These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 19184509)

  • 1. Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity.
    Ghalayini IF; Al-Ghazo MA; Elnasser ZA
    Int Urol Nephrol; 2009 Dec; 41(4):805-13. PubMed ID: 19184509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of electromotive drug administration in delivering botulinum toxin a in children with neuropathic detrusor overactivity-outcomes of a pilot study.
    Koh C; Melling CV; Jennings C; Lewis M; Goyal A
    J Pediatr Urol; 2019 Oct; 15(5):552.e1-552.e8. PubMed ID: 31326328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence.
    Grosse J; Kramer G; Stöhrer M
    Eur Urol; 2005 May; 47(5):653-9. PubMed ID: 15826758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction.
    Ghalayini IF; Al-Ghazo MA
    Neurourol Urodyn; 2007; 26(4):531-536. PubMed ID: 17330289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.
    Bottet F; Peyronnet B; Boissier R; Reiss B; Previnaire JG; Manunta A; Kerdraon J; Ruffion A; Lenormand L; Perrouin Verbe B; Gaillet S; Gamé X; Karsenty G;
    Neurourol Urodyn; 2018 Jan; 37(1):291-297. PubMed ID: 28431196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity.
    Gamé X; Khan S; Panicker JN; Kalsi V; Dalton C; Elneil S; Hamid R; Dasgupta P; Fowler CJ
    BJU Int; 2011 Jun; 107(11):1786-92. PubMed ID: 21040367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin.
    Popat R; Apostolidis A; Kalsi V; Gonzales G; Fowler CJ; Dasgupta P
    J Urol; 2005 Sep; 174(3):984-9. PubMed ID: 16094019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study.
    Grosse J; Kramer G; Jakse G
    BJU Int; 2009 Sep; 104(5):651-6. PubMed ID: 19281462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study.
    Denys P; Del Popolo G; Amarenco G; Karsenty G; Le Berre P; Padrazzi B; Picaut P;
    Neurourol Urodyn; 2017 Feb; 36(2):457-462. PubMed ID: 26756554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre.
    Del Popolo G; Filocamo MT; Li Marzi V; Macchiarella A; Cecconi F; Lombardi G; Nicita G
    Eur Urol; 2008 May; 53(5):1013-19. PubMed ID: 17950989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.
    Schurch B; Stöhrer M; Kramer G; Schmid DM; Gaul G; Hauri D
    J Urol; 2000 Sep; 164(3 Pt 1):692-7. PubMed ID: 10953127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot prospective study to evaluate whether the bladder morphology in cystography and/or urodynamic may help predict the response to botulinum toxin a injection in neurogenic bladder refractory to anticholinergics.
    Álvares RA; Araújo ID; Sanches MD
    BMC Urol; 2014 Aug; 14():66. PubMed ID: 25123234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury.
    Chen G; Liao L
    Int Urol Nephrol; 2011 Sep; 43(3):655-62. PubMed ID: 21110094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study.
    Peyronnet B; Castel-Lacanal E; Roumiguie M; Even L; Marque P; Soulié M; Rischmann P; Game X
    Neurourol Urodyn; 2017 Mar; 36(3):734-739. PubMed ID: 27037973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.
    Karsenty G; Denys P; Amarenco G; De Seze M; Gamé X; Haab F; Kerdraon J; Perrouin-Verbe B; Ruffion A; Saussine C; Soler JM; Schurch B; Chartier-Kastler E
    Eur Urol; 2008 Feb; 53(2):275-87. PubMed ID: 17988791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative urodynamic factors predicting outcome of botulinum toxin-A intradetrusor injection in children with neurogenic detrusor overactivity.
    Kim SW; Choi JH; Lee YS; Han SW; Im YJ
    Urology; 2014 Dec; 84(6):1480-4. PubMed ID: 25432842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity.
    Reitz A; Denys P; Fermanian C; Schurch B; Comperat E; Chartier-Kastler E
    Eur Urol; 2007 Dec; 52(6):1729-35. PubMed ID: 17884281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients.
    Deffontaines-Rufin S; Weil M; Verollet D; Peyrat L; Amarenco G
    Int Braz J Urol; 2011; 37(5):642-8. PubMed ID: 22099277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urodynamic effects of propiverine in children and adolescents with neurogenic bladder: results of a prospective long-term study.
    Schulte-Baukloh H; Mürtz G; Heine G; Austin P; Miller K; Michael T; Strugala G; Knispel HH
    J Pediatr Urol; 2012 Aug; 8(4):386-92. PubMed ID: 21907623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder.
    Schulte-Baukloh H; Michael T; Stürzebecher B; Knispel HH
    Eur Urol; 2003 Jul; 44(1):139-43. PubMed ID: 12814690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.